DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for epidermolysis bullosa simplex — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpidermolysis bullosa simplex maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epidermolysis bullosa simplex is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
integrin subunit beta 4 (ITGB4) — ITGB4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3F7R · 2.036 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Epidermolysis bullosa simplex is a rare autosomal dominant genetic condition in which bullous lesions larger than 0.5 cm appear on skin exposed to mechanical friction or minor trauma. Prevention begins with family and patient education, and infants require greater care and control of their environment. Every individual receives a treatment plan tailored to the severity and extent of skin involvement. The 2022 review describes diagnostic approach, preventative considerations, and current treatments but reports no quantitative outcomes such as response rates or survival data.
As the most common clinical type of hereditary epidermolysis bullosa, EBS can be divided into multiple subtypes. According to the site of blisters, it is split into suprabasal and basal types, each including multiple variants. The 2012 review summarises subtypes and variants based on advances in ultrastructural research and discovery of causative genes, but provides no trial results or treatment efficacy numbers.
A 2020 description notes that epidermolysis bullosa is a heterogeneous group of genetically determined mechano-bullous disorders. Blistering occurs in varying degrees of severity and can severely incapacitate the patient. EBS is dominantly inherited, and treatment still remains a major challenge. No drug, response rate, or survival figure appears in any of these three abstracts.
What is still missing is any controlled trial data, any drug specifically tested for EBS, any quantitative measure of benefit, and any patient stratification beyond the genetic subtype. Without funding for randomised trials and validated outcome measures, the gap between description and effective treatment remains unclosed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the Dermatology Nurses’ Association · 2022 · 1 citations
Epidermolysis Bullosa Simplex
AbstractABSTRACT Epidermolysis bullosa simplex (EBS) is a rare autosomal dominant, genetic condition where bullous lesions, larger than 0.5 cm, affect an area of the skin that is exposed to mechanical friction or minor trauma. Prevention of the bullous lesions starts with family and patient education, with infants requiring greater care and control of their environment. Every individual with EBS will have a treatment plan specifically tailored to the severity and extent of skin involvement. This article provides a comprehensive overview of EBS, including diagnostic approach, preventative considerations, and current treatments.
International Journal of Dermatology and Venereology · 2012 · 0 citations
Advances in epidermolysis bullosa simplex
AbstractAs the most common clinical type of hereditary epidermolysis bullosa,epidermolysis bullosa simplex(EBS)can be divided into multiple subtypes.With advances in ultrastructural research and discovery of causative genes,the classification of EBS has experienced several times of revision and perfection.According to the site of blisters,EBS is divided into two subtypes(suprabasal and basal),and each of them includes multiple variants.This paper presents an overview of current knowledge on subtypes and variants of EBS.
Key words:
Epidermolysis bullosa simplex; Protein isoforms; Heredity
Dermatology and Dermatitis · 2020 · 0 citations · open access
Hereditary Epidermolysis Bullosa: New Description
AbstractEpidermolysis bullosa (EB) is a heterogeneous group of genetically determined, mechano-bullous disorders characterized by blister formation in response to mechanical trauma. The blistering of the skin occurs in the varying degrees of severity and can severely incapacitate the life of the afflicted patient. Epidermolysis Bullosa Simplex (EBS), the most commonly occurring type, is dominantly inherited where treatment still remains a major challenge.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
